glp-1 and adhd Agonists Neurodevelopmental Disorders: Ozempic's Emerging Role in | by Dr. Jerry Don Smith Jr. | The ADHD Review Choosing GLP-1 Over ADHD Meds:

For instance, obesity itself may influence thyroid disease risk

*Disclaimer: Major Players sorted in no particular order Recent Industry Developments December 2025: WHO recommended GLP-1 receptor agonists as part of comprehensive adult-obesity care, citing cardio-metabolic benefits

These medicines include injectable formulations such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon BCise), as well as oral semaglutide (Rybelsus)

1998 Jun;42(6):886891

Southern Adelaide Diabetes and Endocrine Service, Flinders Medical Centre, Bedford Park, SA 5042, Australia